Supreme Pharmaceuticals has issued 130,000 stock options to a consultant of the company. Each option has an exercise price of $0.77 and is exercisable at any time prior to September 14th, 2021, subject to the terms and conditions of the company's Employee Stock Option Plan.

Last month, Supreme Pharmaceuticals closed the third tranche of its previously announced financing for proceeds of $10,610,625 and aggregate proceeds from three tranches of $14,949,755. The company will use net proceeds of the Financing for the expansion of the company's hybrid greenhouse facility and for general working capital purposes.

"This financing represents a big step in the growth of Supreme," said John Fowler, CEO of Supreme. "We are well positioned to complete our Phase 1 expansion of the hybrid greenhouse to satisfy wholesale demand in excess of current capacity. The participation from existing shareholders, directors, management and local investors from Kincardine demonstrates our stakeholders' confidence in our organization and business plan. We are fortunate to have such a strong and supportive shareholder base moving forward."

For more information:
Supreme Pharmaceuticals
202 – 20 De Boers Dr, Toronto ON
M3J 0H1
Phone: (416) 630-7272